Reserpine Improves Working Memory
- 1 Department of Biological Sciences and Bioengineering, Indian Institute of Technology, Kanpur, India
- 2 Department of Biological Sciences and Bioengineering, Indian Institute of Technology, Kanpur, India
- 3 Department of Biological Sciences and Bioengineering, Indian Institute of Technology, Kanpur, India
- 4 Center for Preclinical and Translational Medicine Research, Central Research Facility, Sri Ramachandra University, Chennai, India
Abstract
Despite exhaustive search, no drug is in sight for AD. Earlier, we reported that reserpine, an antihypertensive and antipsychotic drug, ameliorates Amyloid beta (A β -AD causing peptide) toxicity and confers several positive enhancements in the C. elegans model system. Here, we evaluate whether reserpine can provide protection against working memory and against AD in the mouse model. Reserpine (0.08 mg) was administered orally on alternate days to the non-Tg and accelerated A β deposition (at 2 months of age)and cognitive deficit (4 months of age) developing 5XFAD AD Tg mouse model expressing mutant human APP (3 familial mutations) and human Presenilin1(2 familial mutations) in the neurons, and follow their working memory for 2 months using the spontaneous Y-maze alteration behavioral paradigm. Reserpine enhanced working memory in non-Tg mice and improved the cognitive deficit in the 5XFAD AD Tg mice. Hence, reserpine can be considered for a detailed evaluation in the 3X Tg AD mouse model and a pilot study in AD patients.
- Mori, T., Koyama, N., Segawa, T., Maeda, M., Maruyama, N., Kinoshita, N., Hou, H., Tan, J. and Town, T. (2014) Methylene Blue Modulates β-Secretase, Reverses Cerebral Amyloidosis, and Improves Cognition in Transgenic Mice. Journal of Biological Chemistry, 289, 30303-30317. http://dx.doi.org/10.1074/jbc.M114.568212
- Wollen, K.A. (2010) Alzheimer’s Disease: The Pros and Cons of Pharmaceutical, Nutritional, Botanical, and Stimulatory Therapies, with a Discussion of Treatment Strategies from the Perspective of Patients and Practitioners. Alternative Medicine Review, 15, 223-244.
- Savonenko, A.V., Melnikova, T., Hiatt, A., Li, T., Worley, P.F., Troncoso, J.C., Wong, P.C. and Price, D.L. (2012) Alzheimer’s Therapeutics: Translation of Preclinical Science to Clinical Drug Development. Neuropsychopharmacology, 37, 261-277. http://dx.doi.org/10.1038/npp.2011.211
- Doody, R.S., Thomas, R.G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P.S., Siemers, E., Liu-Seifert, H., Mohs, R., Alzheimer’s Disease Cooperative Study Steering Committee and Solanezumab Study Group (2014) Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer’s Disease. The New England Journal of Medicine, 370, 311-321. http://dx.doi.org/10.1056/NEJMoa1312889
- Glenner, G.G. and Wong, C. (1984) Alzheimer’s disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein. Biochemical and Biophysical Research Communications, 120, 885-890.
- Selkoe, D.J. (2001) Alzheimer’s Disease: Genes, Proteins, and Therapy. Physiological Reviews, 81, 741-746.
- Song, M.S., Rauw, G., Baker, G.B. and Kar, S. (2008) Memantine Protects Rat Cortical Cultured Neurons against Beta-Amyloid-Induced Toxicity by Attenuating Tau Phosphorylation. European Journal of Neuroscience, 28, 1989-2002.
- Lopez, O.L. and DeKosky, S.T. (2003) Neuropathology of Alzheimer’s disease and Mild Cognitive Impairment. Review Neurology, 37, 155-163.
- Borchelt, D.R., Ratovitski, T., van Lare, J., Lee, M.K., Gonzales, V., Jenkins, N.A., Copeland, N.G., Price, D.L. and Sisodia, S. (1997) Accelerated Amyloid Deposition in the Brains of Transgenic mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins. Neuron, 19, 939-945. http://dx.doi.org/10.1016/S0896-6273(00)80974-5
- Oakley, H., Cole, S.L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., Berry, R. and Vassar, R. (2006) Intraneuronal Beta-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer’s Disease Mutations: Potential Factors in Amyloid Plaque Fomation. The Journal of Neuroscience, 26, 10129-10140. http://dx.doi.org/10.1523/JNEUROSCI.1202-06.2006